Secretin

What is Secretin?

Secretin is a 27-amino-acid peptide hormone produced and released by S cells of the duodenal and proximal jejunal mucosa in response to acidic chyme arriving from the stomach. It is the founding member of the secretin/glucagon/VIP/GIP/GLP peptide family, a structurally related set of GI and metabolic peptides that all signal through class B (secretin-family) G-protein-coupled receptors. Secretin's primary physiologic action is to stimulate copious bicarbonate-rich, low-enzyme fluid secretion from pancreatic ductal epithelium, which neutralizes duodenal acid and creates the alkaline pH required for pancreatic enzyme function and bile-acid solubility. It also modulates gastric acid secretion, primarily by stimulating somatostatin release from gastric D cells, and contributes to bicarbonate handling in the biliary tree, duodenal Brunner's glands, and (as more recent work has shown) the kidney. Secretin holds an unmatched place in endocrine history: in 1902, William Bayliss and Ernest Starling at University College London demonstrated that an acidified jejunal extract injected into the bloodstream stimulated pancreatic secretion even after all nervous connections to the pancreas had been severed — proof that a chemical messenger, carried in blood, could coordinate distant organs. Three years later Starling coined the word 'hormone' (from the Greek hormao, 'to set in motion') with secretin as the founding example. The 27-residue amino-acid sequence was determined by Viktor Mutt and colleagues at the Karolinska Institute in 1970, and the secretin receptor — the eponymous founding member of class B GPCRs — was molecularly cloned by Ishihara, Nagata, and colleagues in 1991. Today, synthetic human secretin is sold under the brand name ChiRhoStim (ChiRhoClin) and is FDA-approved as a diagnostic reagent for pancreatic-function evaluation, the secretin-stimulation test for gastrinoma in suspected Zollinger-Ellison syndrome, and secretin-enhanced magnetic resonance cholangiopancreatography (S-MRCP). It is not a therapeutic — its role in modern medicine is purely diagnostic.

What Secretin Is Investigated For

Secretin's day-to-day relevance in modern medicine is diagnostic, not therapeutic. Synthetic human secretin (ChiRhoStim) is FDA-approved for three uses: stimulating pancreatic secretion during endoscopic or duodenal-aspirate pancreatic-function testing in suspected chronic pancreatitis or pancreatic insufficiency; provoking a paradoxical rise in serum gastrin in patients with gastrinoma (the secretin stimulation test, which remains the most accurate biochemical confirmation of Zollinger-Ellison syndrome when fasting gastrin and gastric pH are equivocal); and enhancing magnetic resonance cholangiopancreatography (S-MRCP), where IV secretin transiently distends pancreatic ducts with bicarbonate-rich fluid, dramatically improving visualization of ductal anatomy, anomalies, and functional reserve. The historical dimension — secretin as the first hormone ever discovered, the molecule that gave us the word 'hormone' — is the other reason laypeople and biology students encounter the name. The autism story is a cautionary tale: a single 1998 anecdotal report of behavioral improvement after secretin given for an unrelated GI workup ignited intense parent demand and a brief commercial market for secretin infusions, but the rigorous Sandler 1999 NEJM RCT showed no benefit, and the Cochrane 2012 systematic review confirmed across 16 trials and over 900 children that secretin does not improve any core feature of autism. There is no therapeutic indication for secretin in any jurisdiction.

History & Discovery

Secretin holds a unique position in the history of medicine: it is the first hormone ever discovered, and the molecule whose discovery created the entire endocrine paradigm. In January 1902 at University College London, William Bayliss and Ernest Starling carried out one of the most consequential experiments in physiology. The prevailing view, championed by Pavlov, was that pancreatic secretion was triggered by reflex nervous signals from the duodenum. Bayliss and Starling sectioned all nervous connections to the pancreas of an anesthetized dog, then introduced acid into a denervated jejunal loop. The pancreas still secreted copiously. They prepared an acid extract of jejunal mucosa, injected it intravenously, and again the pancreas secreted — proof that a chemical substance, carried in the blood from the small intestine, was the trigger. They named the substance 'secretin.' Three years later, in his 1905 Croonian Lectures to the Royal College of Physicians, Starling proposed the word 'hormone' (from the Greek hormao, meaning 'to set in motion' or 'I excite') as a general term for blood-borne chemical messengers, with secretin as his founding example. Endocrinology — the entire discipline — owes its vocabulary and its conceptual foundation to secretin. For decades after 1902, secretin remained a biological activity in extracts rather than a defined molecule. The 27-amino-acid primary sequence was finally determined by Viktor Mutt, J. Erik Jorpes, and Staffan Magnusson at the Karolinska Institute in 1970, after Mutt's group had pioneered large-scale purification of GI peptides from porcine intestine using their characteristic C-terminal-amide detection chemistry — the same chemistry that would yield CCK, VIP, neuropeptide Y, peptide YY, and galanin from the same Stockholm laboratory. The synthesis of biologically active secretin in the 1970s set the stage for clinical diagnostic use. The molecular cloning of the secretin receptor was accomplished by Tatsuya Ishihara, Shoji Nakamura, Yoshito Kaziro, Tomoyuki Takahashi, Kentaro Takahashi, and Shigekazu Nagata in 1991 (EMBO Journal) — a paper of unusual historical importance because the cloned secretin receptor became the founding member and namesake of the entire class B (secretin-family) GPCR superfamily, a structurally distinct GPCR class that includes the receptors for VIP, PACAP, glucagon, GLP-1, GLP-2, GIP, GHRH, PTH, calcitonin, and CRH. Clinically, secretin moved from physiological curiosity to diagnostic reagent over the second half of the twentieth century. The Dreiling-tube secretin stimulation test, performed by oroduodenal aspiration after IV secretin and developed in the 1950s, was for decades the gold standard for evaluating pancreatic exocrine function. The secretin stimulation test for gastrinoma — exploiting the paradoxical gastrin rise in Zollinger-Ellison syndrome — became established in the 1970s and 1980s and was rigorously validated in the Berna et al. 2006 NIH series. Secretin-enhanced MRCP entered practice in the 1990s and 2000s as MR imaging matured. ChiRhoStim, the synthetic human secretin product made by ChiRhoClin, received FDA approval for pancreatic-function testing in 2004 and for the gastrinoma stimulation test and S-MRCP in subsequent label extensions, replacing the older porcine product Secretin-Ferring in U.S. practice. The most public chapter in modern secretin history is the autism episode. In 1998 a small clinical observation by Horvath and colleagues reported behavioral improvement in three autistic children who had received IV secretin during diagnostic endoscopy for unrelated GI symptoms. Within months, parents were seeking out compounding pharmacies and traveling for off-label secretin infusions; demand was so intense that there was a brief commercial market for the procedure. Adrian Sandler and colleagues conducted the first rigorous randomized placebo-controlled trial in 60 children, published in NEJM in December 1999, and found no benefit. The Cochrane systematic review (Williams, Wray, Wheeler, 2012) pooled 16 trials and over 900 children and definitively concluded that secretin does not improve autism. The episode is a textbook example of how a single anecdotal observation, amplified by media and parental hope, can outrun the evidence — and how rigorous trials can ultimately put a treatment claim to rest.

How It Works

Secretin is a small protein your duodenum makes when stomach acid arrives in your small intestine. It travels through the bloodstream to your pancreas, where it docks onto a receptor and tells the pancreas to pump out alkaline bicarbonate-rich juice. That juice neutralizes the acid, protecting your gut and creating the right pH for your digestive enzymes to work. It also tells your stomach to dial back acid production through a chain of signaling. Doctors give synthetic secretin as an IV injection to make the pancreas reveal whether it is working properly — either by measuring what it produces, by lighting up the pancreatic ducts on MRI, or by triggering a tell-tale gastrin spike that confirms a rare hormone-producing tumor.

Secretin is encoded by the SCT gene on chromosome 11p15 and is processed from a 121-amino-acid preprohormone to the mature 27-residue amidated peptide. It is produced almost exclusively by S cells, an enteroendocrine population scattered throughout the duodenal and proximal jejunal mucosa, with sparser expression also documented in gastric antrum and proximal pancreatic ducts. The dominant physiologic stimulus for secretin release is luminal acidification — chyme of pH < 4.5 entering the duodenum triggers S-cell secretion in proportion to acid load. Bile acids and fatty acids contribute additional, weaker stimuli. Secretin signals through a single receptor, the secretin receptor (SCTR), encoded by the SCTR gene and molecularly cloned by Ishihara, Nakamura, Kaziro, Takahashi, and Nagata in 1991 — the founding member of class B (secretin-family) G-protein-coupled receptors. The class B family also includes the receptors for VIP, PACAP, glucagon, GLP-1, GLP-2, GIP, GHRH, PTH, calcitonin, and CRH; all share a characteristic large extracellular N-terminal domain that contributes the primary peptide-binding interface. The secretin receptor couples primarily to Gs, activating adenylate cyclase and raising intracellular cAMP, which drives pancreatic ductal CFTR-mediated chloride efflux, anion-exchanger-mediated bicarbonate secretion, and aquaporin-mediated water flux — the cellular substrate for the copious bicarbonate-rich pancreatic fluid response. Secondary coupling to Gq/calcium signaling has also been documented in some tissue contexts. The principal physiologic targets are pancreatic ductal epithelium (bicarbonate and water secretion), biliary epithelium (cholangiocyte bicarbonate secretion contributing to bile alkalinization), duodenal Brunner's glands (mucus and bicarbonate), and gastric mucosa (where secretin inhibits gastric acid largely indirectly, by stimulating somatostatin release from antral D cells, which then suppresses parietal-cell acid secretion). More recent work has expanded the catalog to include kidney (where the secretin receptor on intercalated cells contributes to bicarbonate homeostasis — Berg, Leipziger, and colleagues have framed secretin as a systemic 'bicarbonate hormone'), brown adipose tissue (where secretin contributes to meal-induced thermogenesis and central satiety in mice), and central nervous system effects on water and food intake. The diagnostic exploitation of secretin biology rests on three properties: (1) the brisk and reliable pancreatic ductal response (used in pancreatic-function testing and S-MRCP), (2) the paradoxical gastrinoma response (in which gastrinoma cells aberrantly express secretin receptors and respond to secretin with gastrin release rather than the normal suppression), and (3) the rapid, transient kinetics of an IV bolus that allow controlled provocation testing within a single imaging or sampling session.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Secretin:

• 01Whether the recently characterized renal and brown-adipose-tissue actions of secretin are physiologically meaningful in humans, or are predominantly rodent findings — the 'secretin as systemic bicarbonate hormone' framing developed by Berg, Leipziger, and colleagues has clear preclinical support but limited human validation.
• 02Whether secretin-enhanced MRCP can reliably replace direct pancreatic-function testing for diagnosing early chronic pancreatitis — the imaging modality is increasingly preferred for patient comfort, but its sensitivity and specificity at very-early disease stages remain debated.
• 03Whether the 120 pg/mL gastrin-rise threshold from the Berna et al. 2006 NIH series is optimal in the modern era of widespread PPI use, or whether refinement of cut-offs and timing in PPI-treated populations would improve diagnostic accuracy.
• 04Whether secretin contributes meaningfully to central satiety and energy balance in humans, as recent mouse work suggests — and whether secretin biology has any tractable therapeutic angle in obesity or thermogenesis.
• 05Whether agonists or antagonists at the secretin receptor have any therapeutic potential beyond the established diagnostic uses — despite a cloned, well-characterized receptor for over three decades, no SCTR-targeted drug has reached approval for any indication.
• 06Whether subtle interactions between secretin signaling and CFTR function in cystic fibrosis pancreatic and biliary disease offer a therapeutic angle — preliminary work in CF populations using S-MRCP has been illuminating but has not translated.
• 07Whether the very rare pediatric and neurodevelopmental contexts in which exogenous secretin has been tested off-label (beyond autism) hold any genuine signal, or whether the field should consider the question definitively closed after the Cochrane 2012 review.

Forms & Administration

The only commercially available, FDA-approved formulation is synthetic human secretin marketed as ChiRhoStim by ChiRhoClin (also developed under the code RG1068). It is supplied as a sterile lyophilized powder in single-use vials, reconstituted with saline immediately before use, and administered as a slow intravenous bolus (typically over one minute). Standard diagnostic dosing is 0.2 mcg/kg for pancreatic-function testing and S-MRCP and 0.4 mcg/kg for the secretin-stimulation test for gastrinoma. ChiRhoStim is not formulated for chronic dosing, subcutaneous administration, or any therapeutic indication — its label is restricted to single-dose diagnostic use under physician supervision, typically in an endoscopy suite, radiology suite, or dedicated procedure room with monitoring. Earlier porcine secretin preparations (Secretin-Ferring, Secrelux) were withdrawn from the U.S. market when synthetic human secretin became available; porcine product remains in limited international use. Compounded secretin from peptide marketplaces has no validated clinical indication, no quality control, and no place in legitimate medical use.

Common Questions

Who Secretin Is NOT For

Drug & Supplement Interactions

Because secretin is a single-dose IV diagnostic reagent rather than a chronic therapeutic, the relevant interactions are largely test-interference rather than pharmacokinetic. Proton pump inhibitors (omeprazole, pantoprazole, lansoprazole, esomeprazole, rabeprazole) elevate baseline gastrin and can produce false-positive results on the secretin stimulation test for gastrinoma; they should be discontinued for approximately one week before testing when clinically safe (Goldman et al. 2009). H2-receptor antagonists (famotidine, ranitidine, cimetidine) have a similar but smaller effect and are typically held for 48-72 hours. Anticholinergics, somatostatin analogs (octreotide, lanreotide), and H1 antihistamines may blunt the pancreatic secretory response and complicate pancreatic-function-test interpretation. There are no clinically meaningful drug-drug interactions in the conventional pharmacokinetic sense for a single IV bolus. Concurrent use of glucagon (sometimes given for duodenal hypotonia during MRCP) is acceptable and routine. Outside diagnostic use, there is no validated therapeutic interaction profile because there is no therapeutic indication.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions